Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

OCUL

Ocular Therapeutix Inc

Dec 20 • 04:00PM ET

8.50

Dollar change +0.05
Percentage change 0.59	%

Healthcare • Biotechnology • USA • NASD

Peers: LLY GILD JNJ AMGN BIIB BMRN ALKS INCY AGIO ELAN

| Held by: VTI IWM VXF IWO VTWO PJP SCHA DWAS VHT IWC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.32	Insider Own	13.72%	Shs Outstand	156.65M	Perf Week	-2.19%
Market Cap	1.34B	Forward P/E	-	EPS next Y	-1.07	Insider Trans	-0.23%	Shs Float	135.64M	Perf Month	-3.19%
Income	-174.34M	PEG	-	EPS next Q	-0.25	Inst Own	77.39%	Short Float	7.86%	Perf Quarter	0.47%
Sales	61.44M	P/S	21.88	EPS this Y	-16.86%	Inst Trans	2.46%	Short Ratio	9.32	Perf Half Y	30.17%
Book/sh	2.25	P/B	3.78	EPS next Y	9.68%	ROA	-53.42%	Short Interest	10.66M	Perf Year	116.84%
Cash/sh	2.70	P/C	3.15	EPS next 5Y	-	ROE	-96.89%	52W Range	3.76 - 11.77	Perf YTD	90.58%
Dividend Est.	-	P/FCF	-	EPS past 5Y	8.38%	ROI	-40.98%	52W High	-27.81%	Beta	1.23
Dividend TTM	-	Quick Ratio	12.94	Sales past 5Y	121.20%	Gross Margin	90.59%	52W Low	126.07%	ATR (14)	0.52
Dividend Ex-Date	-	Current Ratio	13.01	EPS Y/Y TTM	-52.56%	Oper. Margin	-229.90%	RSI (14)	38.29	Volatility	5.81% 5.77%
Employees	267	Debt/Eq	0.21	Sales Y/Y TTM	6.45%	Profit Margin	-283.74%	Recom	1.10	Target Price	18.30
Option/Short	Yes / Yes	LT Debt/Eq	0.21	EPS Q/Q	13.74%	Payout	-	Rel Volume	1.25	Prev Close	8.45
Sales Surprise	-9.94%	EPS Surprise	9.35%	Sales Q/Q	2.28%	Earnings	Nov 14 BMO	Avg Volume	1.14M	Price	8.50
SMA20	-7.85%	SMA50	-14.81%	SMA200	4.10%	Trades		Volume	1,431,144	Change	0.59%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Jun-20-24	Upgrade	TD Cowen	Hold → Buy	$7 → $11
May-31-24	Resumed	Piper Sandler	Overweight	$15
Feb-09-24	Initiated	BofA Securities	Buy	$15
Apr-21-23	Initiated	Robert W. Baird	Outperform	$18
Aug-10-22	Resumed	Berenberg	Buy	$15
Aug-10-21	Upgrade	H.C. Wainwright	Neutral → Buy	$17
Dec-28-20	Downgrade	H.C. Wainwright	Buy → Neutral
Dec-17-20	Initiated	Berenberg	Buy	$27
Nov-13-20	Reiterated	Raymond James	Strong Buy	$15 → $25
Aug-10-20	Reiterated	H.C. Wainwright	Buy	$10 → $13
Mar-03-20	Upgrade	Raymond James	Outperform → Strong Buy
May-21-19	Reiterated	H.C. Wainwright	Buy	$12 → $9
May-21-19	Downgrade	Raymond James	Strong Buy → Outperform	$11 → $5
May-21-19	Downgrade	Cowen	Outperform → Market Perform	$13 → $3
Dec-03-18	Reiterated	Cantor Fitzgerald	Overweight	$22 → $24
Nov-15-18	Initiated	Raymond James	Strong Buy	$10
Sep-07-18	Initiated	Piper Jaffray	Overweight
Oct-24-17	Initiated	Guggenheim	Buy	$12
Jul-26-17	Initiated	H.C. Wainwright	Buy	$10

Show Previous Ratings

Dec-13-24 07:00AM	Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-10-24 07:30AM	Ocular Therapeutix to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-03-24 07:47AM	Ocular Therapeutix announces over 300 subjects randomized in SOL-1 (TipRanks)
Dec-02-24 07:30AM	Ocular Therapeutix Announces More Than 300 Subjects Randomized in SOL-1 (GlobeNewswire)
Nov-26-24 07:30AM	Ocular Therapeutix to Participate in December Investor and Scientific Conferences (GlobeNewswire) +7.26%
02:06AM	Loading…
Nov-15-24 02:06AM	Ocular Therapeutix Inc (OCUL) Q3 2024 Earnings Call Highlights: Strong Financial Position and ... (GuruFocus.com) -7.66%
Nov-14-24 08:40AM	Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -6.42%
07:37AM	Ocular Therapeutix: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Ocular Therapeutix Reports Third Quarter 2024 Results and Business Highlights (GlobeNewswire)
Nov-13-24 07:30AM	Ocular Therapeutix to Present at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV (GlobeNewswire)
07:17AM	What To Expect From Ocular Therapeutix Inc (OCUL) Q3 2024 Earnings (GuruFocus.com)
Nov-12-24 07:30AM	Ocular Therapeutix Appoints Namrata Saroj, OD, as Chief Business Officer (GlobeNewswire)
Nov-06-24 07:30AM	Ocular Therapeutix to Report Third Quarter 2024 Results on November 14, 2024 (GlobeNewswire)
Oct-15-24 07:30AM	Ocular Therapeutix Announces Accelerated Timelines for SOL-1 Registrational Trial of AXPAXLI in Wet AMD (GlobeNewswire)
Oct-14-24 09:59AM	Ocular Therapeutix (OCUL) Moves 6.1% Higher: Will This Strength Last? (Zacks) +6.95%
04:05PM	Loading…
Oct-09-24 04:05PM	Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:30AM	Ocular Therapeutix to Present at October Ophthalmology Meetings (GlobeNewswire)
Oct-08-24 08:50AM	Here's What Could Help Ocular Therapeutix (OCUL) Maintain Its Recent Price Strength (Zacks)
Sep-25-24 07:30AM	Ocular Therapeutix to Present at the UBS Virtual Opthalmology Day 2024 (GlobeNewswire)
Sep-12-24 04:05PM	Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-05-24 07:30AM	Ocular Therapeutix to Present at September Retina Meetings (GlobeNewswire)
Sep-04-24 07:30AM	Ocular Therapeutix to Present at Two Investor Conferences in September (GlobeNewswire)
Aug-09-24 09:55AM	Wall Street Analysts See an 85.43% Upside in Ocular Therapeutix (OCUL): Can the Stock Really Move This High? (Zacks)
07:30AM	Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-07-24 08:45AM	Ocular Therapeutix (OCUL) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +6.08%
07:38AM	Ocular Therapeutix: Q2 Earnings Snapshot (Associated Press Finance)
07:10AM	Ocular Therapeutix Reports Second Quarter 2024 Results (GlobeNewswire)
07:00AM	Ocular Therapeutix Announces FDA Feedback That SOL-R Trial is Appropriate as a Registrational Study in Wet AMD (GlobeNewswire)
Jul-31-24 07:30AM	Ocular Therapeutix to Report Second Quarter 2024 Financial Results on August 7, 2024 (GlobeNewswire)
Jul-30-24 07:30AM	Ocular Therapeutix Announces First Patients Enrolled in Phase 3 SOL-R Wet AMD Study (GlobeNewswire)
04:05PM	Loading…
Jul-18-24 04:05PM	Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-10-24 08:00AM	Ocular Therapeutix Announces Late-Breaking Abstract of HELIOS Study to be Presented at 42nd ASRS Annual Scientific Meeting (GlobeNewswire) +11.01%
Jul-08-24 04:05PM	Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-13-24 04:05PM	Ocular Therapeutix Highlights Exceptional AXPAXLI SOL-1 Enrollment and Plans for Repeat Dosing Study (SOL-R) in wet AMD at Investor Day, Along with Positive 48-week Data from HELIOS NPDR Study (GlobeNewswire) +14.09%
Jun-05-24 07:30AM	Ocular Therapeutix to Host Investor Day on June 13, 2024 (GlobeNewswire)
Jun-04-24 04:05PM	Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-07-24 09:01PM	OCUL Stock Earnings: Ocular Therapeutix Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
06:07PM	Ocular Therapeutix Inc Reports First Quarter 2024 Earnings (GuruFocus.com)
04:41PM	Ocular Therapeutix: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Ocular Therapeutix Reports First Quarter 2024 Results (GlobeNewswire)
May-06-24 08:16PM	Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.00%
07:30AM	Ocular Therapeutix to Present at Two Upcoming Investor Conferences (GlobeNewswire)
May-03-24 07:30AM	Ocular Therapeutix To Present at Two Ophthalmology Meetings, May 4-9, 2024 (GlobeNewswire) +5.11%
May-01-24 07:30AM	Ocular Therapeutix to Host Investor Day in New York City on Thursday, June 13, 2024 (GlobeNewswire) +5.91%
Apr-24-24 08:30AM	2 Small-Cap Growth Stocks With Room to Run (Motley Fool) -7.10%
Apr-18-24 03:37PM	Ocular Therapeutix Highlights Early Data From Diabetes-Related Eye Disorder (Benzinga) -22.69%
07:00AM	Ocular Therapeutix Announces Positive Topline Phase 1 Data for AXPAXLI in Diabetic Retinopathy (GlobeNewswire)
Apr-16-24 04:30PM	The 3 Best Biotech Stocks to Buy Now: Q2 Edition (InvestorPlace)
07:00AM	Ocular Therapeutix Strengthens Clinical Team with Appointment of Key Retinal Leaders (GlobeNewswire)
Apr-15-24 07:00AM	Ocular Therapeutix Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO (GlobeNewswire)
Apr-09-24 09:35AM	Down -17.88% in 4 Weeks, Here's Why Ocular Therapeutix (OCUL) Looks Ripe for a Turnaround (Zacks)
07:30AM	Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics (GlobeNewswire)
Apr-06-24 10:00AM	Ocular Therapeutix Announces Positive Phase 2 PAXTRAVA Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting (GlobeNewswire)
Apr-01-24 10:09AM	Million-Dollar Bets: 3 Under-$15 Stocks With Massive Potential (InvestorPlace)
Mar-26-24 07:30AM	Ocular Therapeutix To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract and Refractive Surgery) (GlobeNewswire)
Mar-13-24 06:38AM	Q4 2023 Clearside Biomedical Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-12-24 09:55AM	Wall Street Analysts Think Ocular Therapeutix (OCUL) Could Surge 34.74%: Read This Before Placing a Bet (Zacks)
Mar-11-24 05:32PM	Ocular Therapeutix Inc Reports Growth Amidst Strategic Shifts (GuruFocus.com)
05:25PM	Ocular Therapeutix (OCUL) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:26PM	Ocular Therapeutix: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Ocular Therapeutix Reports Fourth Quarter and Full Year 2023 Results (GlobeNewswire)
Mar-05-24 07:30AM	Ocular Therapeutix to Release Fourth Quarter and Full Year 2023 Results on March 11, 2024 (GlobeNewswire)
Mar-01-24 06:30PM	Criteo, Ocular Therapeutix, and More Stocks See Action From Activist Investors (Barrons.com) +6.86%
Feb-29-24 08:52AM	Should You Buy Ocular Therapeutix (OCUL) Ahead of Earnings? (Zacks)
Feb-28-24 01:40PM	Hedge Fund and Insider Trading News: Stan Druckenmiller, Warren Buffett, Brevan Howard Asset Management, Citadel LLC, AMN Healthcare Services Inc (AMN), Ocular Therapeutix Inc (OCUL), and More (Insider Monkey)
Feb-26-24 12:00PM	Are You Looking for a Top Momentum Pick? Why Ocular Therapeutix (OCUL) is a Great Choice (Zacks)
10:00AM	Ocular Therapeutix (OCUL) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Feb-25-24 02:02PM	3 Stocks to Buy That Are Up 100% or More in 2024 (InvestorPlace)
Feb-22-24 07:32AM	Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Chairman and Chief Strategy Officer (GlobeNewswire) +28.99%
07:31AM	Ocular Therapeutix, Inc. Announces $325.0 Million Private Placement (GlobeNewswire)
07:30AM	Ocular Therapeutix Announces Board of Directors and Leadership Updates (GlobeNewswire)
Feb-21-24 09:55AM	Wall Street Analysts Believe Ocular Therapeutix (OCUL) Could Rally 64.63%: Here's is How to Trade (Zacks)
Feb-19-24 09:00AM	AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA for Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery, and Ocular Itching Associated with Allergic Conjunctivitis (PR Newswire)
Feb-18-24 08:00PM	AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA® for Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery, and Ocular Itching Associated with Allergic Conjunctivitis (PR Newswire)
Feb-15-24 08:00AM	Ocular Therapeutix Appoints Steve Meyers to Chief Commercial Officer (GlobeNewswire) +6.19%
Feb-13-24 07:37AM	Ocular Therapeutix Announces First Subjects Screened in Phase 3 Pivotal Clinical Trial of AXPAXLI in Wet AMD (GlobeNewswire)
Feb-12-24 06:27AM	Ocular Therapeutix (OCUL) Surges 12.9%: Is This an Indication of Further Gains? (Zacks)
Jan-30-24 09:55AM	Does Ocular Therapeutix (OCUL) Have the Potential to Rally 134.83% as Wall Street Analysts Expect? (Zacks)
Jan-25-24 08:00AM	Ocular Therapeutix Announces FDA Agreement to Amend Special Protocol Assessment (SPA) for Pivotal Clinical Trial of AXPAXLI in Wet AMD (GlobeNewswire) +6.98%
Jan-10-24 08:44AM	Why Ocular Therapeutix (OCUL) Stock Might be a Great Pick (Zacks)
Jan-03-24 01:15PM	Wall Street Thinks These 2 Biotech Stocks Could Soar in 2024 (Motley Fool) -5.61%
Dec-18-23 04:01PM	Ocular Therapeutix Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares (GlobeNewswire) -6.74% +10.23%
Dec-13-23 10:09PM	Ocular Therapeutix Announces Pricing of Public Offering of Common Stock (GlobeNewswire) +12.09%
04:01PM	Ocular Therapeutix Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Nov-08-23 05:18PM	Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q3 2023 Earnings Call Transcript (Insider Monkey) -13.20% -13.39%
08:00AM	Ocular Therapeutix to Present at Three Upcoming Investor Conferences (GlobeNewswire)
Nov-07-23 06:47PM	Ocular Therapeutix: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Ocular Therapeutix Provides Third Quarter 2023 Financial Results and Corporate Update (GlobeNewswire)
Nov-01-23 08:00AM	Ocular Therapeutix Receives FDA Agreement Under Special Protocol Assessment (SPA) for its First Pivotal Clinical Trial of OTX-TKI in Wet AMD (GlobeNewswire) +11.93%
07:06AM	Verve Therapeutics (VERV) Surges 28.0%: Is This an Indication of Further Gains? (Zacks)
Oct-31-23 09:00AM	AffaMed Therapeutics Announced Positive Top-Line Results from Real-World Study in China Evaluating the Safety and Efficacy of DEXTENZA in Patients after Cataract Surgery (PR Newswire) +15.38%
Oct-30-23 09:35PM	AffaMed Therapeutics Announced Positive Top-Line Results from Real-World Study in China Evaluating the Safety and Efficacy of DEXTENZA® in Patients after Cataract Surgery (PR Newswire)
Oct-24-23 08:00AM	Ocular Therapeutix To Report Third Quarter 2023 Financial Results (GlobeNewswire) +5.60%
Oct-03-23 04:01PM	Ocular Therapeutix Announces Initiation of its First Pivotal Clinical Trial of OTX-TKI in Wet AMD (GlobeNewswire) -9.21%
Sep-19-23 09:00PM	AffaMed Therapeutics Announces First Patient Treated in Phase 3 Registrational Clinical Trial in Mainland China for DEXTENZA® for the Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery (PR Newswire)
Sep-06-23 08:00AM	Ocular Therapeutix to Present at Three Upcoming Investor Conferences (GlobeNewswire)
Aug-09-23 08:00AM	Ocular Therapeutix to Present at the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference (GlobeNewswire)
Aug-08-23 11:13AM	Q2 2023 Ocular Therapeutix Inc Earnings Call (Thomson Reuters StreetEvents) -10.78%
Aug-07-23 07:15PM	Ocular Therapeutix (OCUL) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
06:05PM	Ocular Therapeutix: Q2 Earnings Snapshot (Associated Press Finance)

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Heier Jeffrey S.	Chief Scientific Officer	Nov 25 '24	Sale	9.01	2,948	26,561	269,059	Nov 27 07:52 AM
Kaiser Peter	Chief Development Officer	Nov 25 '24	Sale	9.01	2,897	26,102	213,087	Nov 27 07:51 AM
Nayak Sanjay	Chief Strategy Officer	Nov 25 '24	Sale	9.00	1,814	16,326	174,380	Nov 27 07:49 AM
Dugel Pravin	See Remarks	Nov 25 '24	Sale	9.01	20,680	186,327	791,793	Nov 27 07:47 AM
SANJAY NAYAK	Officer	Nov 25 '24	Proposed Sale	8.97	1,814	16,273		Nov 25 06:42 PM
PETER KAZUO KAISER	Officer	Nov 25 '24	Proposed Sale	9.01	2,897	26,095		Nov 25 06:23 PM
PRAVIN DUGEL	Officer	Nov 25 '24	Proposed Sale	9.01	17,783	160,186		Nov 25 06:19 PM
PRAVIN DUGEL	Officer	Nov 25 '24	Proposed Sale	9.01	2,897	26,095		Nov 25 05:44 PM
JEFFREY S. HEIER	Officer	Nov 25 '24	Proposed Sale	9.01	2,948	26,550		Nov 25 05:10 PM
PHILIP C. STRASSBURGER	Officer	Oct 16 '24	Proposed Sale	10.23	13,125	134,269		Oct 16 04:25 PM
Nayak Sanjay	Chief Strategy Officer	Aug 23 '24	Sale	9.02	1,832	16,525	176,194	Aug 27 05:19 PM
Dugel Pravin	See Remarks	Aug 23 '24	Sale	9.02	20,880	188,338	812,473	Aug 27 05:17 PM
RABIA OZDEN	Officer	Aug 27 '24	Proposed Sale	9.00	18,333	164,997		Aug 27 04:18 PM
PRAVIN DUGEL	Officer	Aug 23 '24	Proposed Sale	9.02	20,880	188,271		Aug 23 05:10 PM
SANJAY NAYAK	Officer	Aug 23 '24	Proposed Sale	9.02	1,832	16,526		Aug 23 04:36 PM
RABIA OZDEN	Officer	Aug 21 '24	Proposed Sale	8.90	10,000	89,047		Aug 21 05:32 PM
RABIA OZDEN	Officer	Aug 07 '24	Proposed Sale	8.50	15,000	127,500		Aug 07 04:15 PM
ANTONY MATTESSICH	Former Officer	Aug 01 '24	Proposed Sale	8.19	23,979	196,498		Aug 01 04:30 PM
LINDSTROM RICHARD L MD	Director	Feb 27 '24	Option Exercise	8.80	30,302	266,658	150,704	Jul 26 07:30 PM
Nayak Sanjay	Chief Strategy Officer	May 23 '24	Sale	5.84	2,274	13,280	178,026	May 28 05:01 PM
Dugel Pravin	See Remarks	May 23 '24	Sale	5.79	21,626	125,215	833,353	May 28 05:00 PM
SUMMER ROAD LLC	10% Owner	Feb 26 '24	Buy	7.52	930,851	7,000,000	8,591,401	Feb 27 04:43 PM
Notman Donald	Chief Financial Officer	Jan 31 '24	Sale	4.95	6,433	31,843	139,932	Feb 02 07:03 PM
Ozden Rabia Gurses	Chief Medical Officer	Jan 31 '24	Sale	4.95	7,764	38,432	92,767	Feb 02 07:02 PM
Strassburger Philip C.	General Counsel	Jan 31 '24	Sale	4.95	6,831	33,813	109,218	Feb 02 07:01 PM
White Christopher G	Chief Business Officer	Jan 31 '24	Sale	4.95	5,147	25,478	89,619	Feb 02 07:01 PM
Mattessich Antony C.	President and CEO	Jan 31 '24	Sale	4.95	18,338	90,773	427,943	Feb 02 07:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

OCUL

Ocular Therapeutix Inc

Upgrade your FINVIZ experience